N/A
N=60
Mobile-Based Application "MyChoices"
HIV · Sexually Transmitted Diseases · Pre-exposure Prophylaxis · Risk Reduction
Bottom Line
View on ClinicalTrials.gov: NCT03179319 ↗Enrolled (actual)
60
Serious AEs
0.0%
Results posted
Dec 2020
Primary outcome: Primary: Acceptability: System Usability Scale — 75.76 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- MyChoices (Behavioral)
- Age
- Pediatric, Adult · 15+ yrs
- Sex
- Male
- Sponsor
- Fenway Community Health
- Primary completion
- Dec 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Acceptability: System Usability Scale |
75.76 | — |
| PRIMARY Feasibility: Frequency of Logins |
31 | — |
| SECONDARY Preliminary Efficacy: Number of Participants Self-reported Having Tested for HIV |
27; 13 | — |
| SECONDARY Preliminary Efficacy: Number of Participants Self-reported Having Initiated PrEP |
3; 3 | — |
| SECONDARY Number of Times Participants Used Distinct App Components |
100.58 | — |
| SECONDARY App Content and Functionality Most Utilized |
30; 26; 22; 31 | — |
| SECONDARY Number of HIV Home Testing Kits Ordered |
25 | — |
Summary
This study is testing the acceptability and feasibility of MyChoices, a mobile application (app), to promote HIV testing and pre-exposure prophylaxis (PrEP) uptake among young men who have sex with men (YMSM).
Eligibility Criteria
Inclusion Criteria
- No HIV test in the past 3 months (self-reported).
- Not known to be HIV-infected (self-reported).
- Not currently taking PrEP (self-report).
- Owns or leases a phone with Android platform (for Aims 2 and 3) or iOS platform (Aim 3 only), has an active data plan, and willing to download the MyChoices application.
- Willing to attend an in-person baseline study visit in Boston or the Bronx and complete online follow-up visits.
- Able to understand, read, and speak English.
- Participants ages 15-18: self-report at least one episode of anal intercourse with a male or transfemale partner during the last 6 months.
- Participants ages 19-24: self-report evidence of high risk for acquiring HIV infection including at least one of the following:
- at least one episode of condomless anal intercourse with an HIV-infected or unknown HIV status male or transfemale partner during the last 6 months; or
- anal intercourse with 2 or more male or transfemale sex partners during the last 6 months; or
- exchange of money, gifts, shelter, or drugs for anal sex with a male or transfemale partner during the last 6 months; or
- sex with a male or transfemale partner and has had an STI during the last 6 months.
Exclusion Criteria
- Any health condition that may interfere with participation or the ability to provide informed consent, including any debilitating or life-threatening conditions.
- Prior enrollment in an HIV vaccine trial with receipt of experimental vaccine product and evidence of vaccine-induced seropositivity.
- Known to be HIV-infected.
- Any medical, psychiatric, or social condition or other responsibilities that, in the judgment of the investigator, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
Data sourced from ClinicalTrials.gov (NCT03179319). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.